iNetX Corporation

With 30 years of ocular research and large pharma drug development experience, iNetX Corporation provides expert guidance on nonclinical ophthalmic DMPK strategies and clinical trial-enabling data generation and evaluation. Consulting services include, but are not limited to: • DMPK strategies for every stage of compound/device development • Evaluation of nonclinical data to streamline development effort • Exploratory and IND-enabling ocular PK and TK study design and execution • Compose DMPK-related sections for international regulatory submissions • Ocular therapeutics and technology in-/out-licensing due-diligence • Feasibility assessment of alternative indications for drugs • Staff training and establishing in-house ophthalmic development capabilities